8-K: Globus Medical to Acquire Nevro Corp. for $5.85 Per Share, Expanding Musculoskeletal Technology Portfolio

Globus Medical will acquire Nevro in an all-cash transaction for $5.85 per share, aiming to expand treatment options for patients and create a combined medical technology leader.

Summary

• Globus Medical has entered into a definitive agreement to acquire Nevro Corp. in an all-cash transaction.
• Globus Medical will acquire all outstanding shares of Nevro for $5.85 per share.
• The transaction represents a total equity value of approximately $250 million.
• The acquisition is expected to close late in the second quarter of 2025, pending shareholder and regulatory approvals.
• Globus Medical expects the acquisition to be accretive to its earnings in the second year of operation.
• Globus Medical reaffirms its 2025 net sales guidance of $2.66 billion to $2.69 billion on a stand-alone basis.
• Following the acquisition, Globus Medical anticipates 2025 net sales of $2.80 billion to $2.90 billion and fully diluted non-GAAP earnings per share range between $3.10 to $3.40.
• Nevro announced preliminary 2024 worldwide revenue of $408 million to $409 million.
• Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over the prior year.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the acquisition price may not be ideal for Nevro shareholders, the deal provides Nevro with access to Globus Medical's resources and infrastructure, potentially accelerating growth. Globus Medical also benefits from expanding its product portfolio and market reach.

Positives

• The acquisition allows Globus Medical to expand into new markets and gain access to differentiated technologies in neuromodulation.
• Nevro's products complement Globus Medical's spine portfolio, creating synergies and expanding treatment options.
• Globus Medical's operational capabilities are expected to accelerate market penetration of Nevro's technology.
• The combined company is expected to deliver clinically superior relief to patients suffering from chronic pain.
• Globus Medical's scale and operational discipline are expected to optimize Nevro's financial performance and drive enhanced profitability.
• The acquisition is expected to be accretive to Globus Medical's earnings in the second year of operation.

Negatives

• The acquisition is subject to shareholder and regulatory approvals, which could delay or prevent the transaction from closing.
• The integration of Nevro's business may present challenges and risks for Globus Medical.
• The anticipated synergies and benefits of the acquisition may not be fully realized.
• The transaction could potentially lead to the loss of key personnel at Nevro.

Risks

• The proposed transaction may not be completed in a timely manner or at all.
• Required regulatory approvals may not be obtained, may be delayed, or may be subject to unanticipated conditions.
• The approval of Nevro's stockholders may not be obtained.
• The anticipated benefits of the proposed transaction may not be realized.
• Competing offers or acquisition proposals for Nevro may be made.
• Various conditions to the consummation of the merger may not be satisfied or waived.
• The announcement or pendency of the merger could negatively affect Nevro's ability to retain and hire key personnel or its operating results and business generally.

Future Outlook

Globus Medical expects the Nevro acquisition to be accretive to its earnings in the second year of operation and anticipates increased net sales and earnings per share in 2025 following the consummation of the transaction.

Management Comments

• Dan Scavilla, President and CEO of Globus Medical, stated that the transaction furthers their mission to become the preeminent musculoskeletal technology company and will expand into new markets for future growth.
• Kevin Thornal, Nevro's CEO and President, stated that joining Globus Medical will allow them to reach more patients globally and achieve their full potential to become a broader and more diversified leader in the pain management space.

Industry Context

The acquisition reflects a trend of consolidation in the medical device industry, with larger companies seeking to expand their product portfolios and market reach through strategic acquisitions. Globus Medical's acquisition of Nevro is aimed at strengthening its position in the musculoskeletal technology market and expanding its presence in the pain management space.

Comparison to Industry Standards

• Globus Medical's acquisition of Nevro is similar to other acquisitions in the medical device industry, where larger companies acquire smaller, innovative companies to expand their product offerings and market share.
• Comparable companies in the musculoskeletal technology space include Medtronic, Stryker, and Johnson & Johnson, which have also pursued acquisitions to strengthen their market positions.
• The acquisition price of $5.85 per share represents a premium to Nevro's recent trading prices, which is typical in acquisition transactions.
• The expected accretion to Globus Medical's earnings in the second year of operation is a common goal in acquisitions, as companies seek to realize synergies and improve financial performance.

Stakeholder Impact

• Nevro's shareholders will receive $5.85 per share in cash.
• Nevro's employees may experience changes in their roles and responsibilities following the acquisition.
• Nevro's customers are expected to benefit from the combined company's expanded product offerings and resources.
• Globus Medical's shareholders may see increased value from the acquisition over the long term.

Next Steps

• Nevro will hold a special stockholder meeting to obtain approval for the proposed transaction.
• The parties will seek regulatory approval for the transaction.
• Globus Medical and Nevro will work to integrate their businesses following the closing of the transaction.

Key Dates

Keywords

acquisition, merger, Globus Medical, Nevro, musculoskeletal, neuromodulation, chronic pain, spinal cord stimulation, SCS, SI joint fusion